27/05/2026
Gene Therapy Is Transforming How We Treat Neurological Diseases
Imagine a world where Alzheimer's, Parkinson's, and ALS are not life sentences but treatable conditions addressed at their genetic root. That world is closer than most people realize.
The Gene Therapy On Neurological Diseases market is projected to grow from $4.99 billion in 2025 to $15.40 billion by 2034, driven by breakthroughs in CRISPR gene editing, advanced AAV vector delivery systems, and record levels of pharmaceutical investment.
Conditions that once had no curative pathway are now active targets for gene-based interventions. Companies like Novartis, Biogen, Roche, and Voyager Therapeutics are racing to bring next-generation therapies to patients who have waited far too long.
The science is real. The investment is accelerating. The results are arriving in clinics worldwide.
Neurological medicine is entering its most important decade yet. Follow our page for the latest market insights and research updates.
https://www.strategicrevenueinsights.com/industry/gene-therapy-on-neurological-diseases-market